Clinical trials: Major Depressive Disorder, completed
Major Depressive Disorder
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder
This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive…
- Trial name
- NCT00095823
- Testing
- Antidepressant + Aripiprazole
- Where
- 20 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depression
Research Study for Major Depressive Disorder: Investigation of Glutamate Medications
This study is examining the safety and effectiveness of two medications, ketamine and riluzole, in treating patients with treatment resistant major depressive disorder.
- Trial name
- NCT00419003
- Testing
- Lamotrigine, Ketamine, Riluzole
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Baylor College of Medicine
Depression
E-Mental Health Adolescent Depression Program (LEAP)
The purpose of this project is to explore the potential value and practicality of an innovative depression intervention for young people. More specifically, the objectives of this project are: 1.
- Trial name
- LEAP (NCT00985686)
- Testing
- LEAP Project
- Where
- Canada
- Volunteers
- 63 people
- Sponsor
- Patricia Steele
Major Depressive Disorder, Traumatic Brain Injury
Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury
Cognitive behavioral therapy for major depressive disorder (MDD) was adapted for individuals with moderate to severe traumatic brain injury (TBI) (CBT-TBI). A structured, treatment manual was developed.
- Trial name
- NCT03307070
- Testing
- Cognitive Behavioral Therapy for individuals with TBI, Waitlist Control
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital
Treatment Resistant Depression
Deciphering Principles of Network Dynamics Underlying Depression Symptom Severity From Multi-day Intracranial Recordings in Patients With Major Depression
Major depressive disorder (MDD) is common and causes significant disability world-wide. While typically responsive to medications and therapy, there remain a subset of patients who are treatment resistant.
- Trial name
- NCT06953362
- Testing
- Direct Neural Electrical Stimulation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Major Depressive Disorder
Transcranial Direct Current Stimulation (tDCS) in Young Individuals with Major Depressive Disorder: a Literature Review and Feasibility Study
Objectives: (1) To assess the therapeutic effects of tDCS on improving depressive symptoms in young individuals with Major Depressive Disorder (MDD), relative to sham stimulation ; and (2) to evaluate the tolerability, and…
- Trial name
- NCT06518642
- Testing
- Sooma tDCS portable device - active stimulation
- Where
- Hong Kong
- Volunteers
- 8 people
- Sponsor
- The University of Hong Kong
Major Depressive Disorder (MDD)
European Drug Utilization Study
The purpose of this retrospective observational study is to evaluate the characteristics of patients receiving Seroquel XR as treatment for their Major Depressive Disorder.
- Trial name
- EUDUS (NCT01594996)
- Where
- Germany
- Volunteers
- 814 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Early Prediction of Fluoxetine Response
The purpose of this study is to identify what degree of symptom changes during the early weeks could be used to predict eventual nonresponse at week 6 among depressive inpatients taking fluoxetine.
- Trial name
- NCT01075529
- Testing
- fluoxetine
- Where
- Taiwan
- Volunteers
- 140 people
- Sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital
Major Depressive Disorder
Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression
Major depressive disorder (MDD) is a highly prevalent, chronic and/or recurrent condition with substantial morbidity and mortality. It is one of the leading causes of disability worldwide.
- Trial name
- NCT02132286
- Testing
- Quetiapine XR (extended release)
- Where
- Canada
- Volunteers
- 57 people
- Sponsor
- University of Calgary
Parkinson's Disease, Major Depressive Disorder
Antidepressant Effect of Deep Brain Stimulation in Parkinson's Disease Patients
The purpose of this study is: 1. To determine, in the context of a prospective clinical trial, whether stimulation parameters in PD patients treated with DBS, are associated with antidepressant effects. 2.
- Trial name
- NCT00885222
- Testing
- DBS parameters setting
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization
Depressive Disorder, Major
A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS)
The purpose of this study is to determine whether the Cervel Neurotech rTMS device is safe and effective in the treatment of depression in people who do not get better with antidepressant medications or cannot take antidepressant…
- Trial name
- NCT01909232
- Testing
- Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator, Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
- Where
- 6 sites in United States
- Volunteers
- 92 people
- Sponsor
- Cervel Neurotech, Inc.
Depression
Comparison of Two Psychotherapy Treatments for Depressed Women With a History of Sexual Abuse
This study will compare the effectiveness of individual versus interpersonal psychotherapy in treating depressed women with a history of sexual abuse.
- Trial name
- NCT00257400
- Testing
- Interpersonal Psychotherapy (IPT), Individual Psychotherapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Rochester
Major Depressive Disorder
Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers
The purpose of this study is to assess the safety and tolerability of multiple oral (PO) ascending doses of NRX-1074 in normal healthy volunteers.
- Trial name
- NRX-1074 (NCT02366364)
- Testing
- NRX-1074 375 mg, NRX-1074 500 mg, NRX-1074 750 mg
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Depression
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major…
- Trial name
- NCT01072630
- Testing
- Armodafinil
- Where
- 92 sites in United States, Argentina and 8 more
- Volunteers
- 492 people
- Sponsor
- Cephalon
MDD
Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder
This an open label study using a FDA-cleared TMS stimulation protocols which will be used to treat patients who have responded or remitted from depression using acute clinical TMS therapy at the University of Missouri-Columbia…
- Trial name
- NCT04076644
- Testing
- TMS treatment
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Missouri-Columbia
Major Depressive Disorder
Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve depressive symptoms in elderly patients with major…
- Trial name
- NCT00388973
- Testing
- Quetiapine
- Where
- 43 sites in United States, Argentina and 4 more
- Volunteers
- 338 people
- Sponsor
- AstraZeneca
Depressive Disorder
Nicotinic Receptor Augmentation of SSRI Antidepressants
The purpose of this study is to determine whether the nicotinic receptor antagonist mecamylamine hydrochloride (Inversine) can augment SSRI-refractory major depression symptoms, quality of life and cigarette smoking outcomes.
- Trial name
- NCT00319319
- Testing
- Mecamylamine hydrochloride (Inversine)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
The goals of this study are to replicate previous findings of genetic predictors of response to clozapine and other antipsychotic drugs.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
- Trial name
- NCT00178932
- Testing
- genetic analysis, genetic assay
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Major Depressive Episode
The Role of Expectations in the Pharmacological Treatment of Depression - An Experimental Investigation
The study aimes at identifying whether positive expectations have an impact on the way depressive participants experience emotions in the form of sadness.
- Trial name
- NCT03190772
- Testing
- Film sequence
- Where
- 2 sites in Germany
- Volunteers
- 94 people
- Sponsor
- Philipps University Marburg
Psychiatric Disorder, Major Depressive Disorder
Exploring Blood Plasma Metabolomics: Unraveling the Metabolic Landscape in Treatment-Resistant Adolescent Depression
This study contributes new evidence for the identification of adolescent TRD and sheds light on differing pathophysiologies by delineating distinct plasma metabolic profiles between adolescent TRD and FEDN-MDD.
- Conditions
- Psychiatric Disorder, Major Depressive Disorder, Metabolic Disorder
- Trial name
- NCT06331572
- Testing
- 17-HAMD
- Where
- China
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.